Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | TEK | Q02763 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026328 | 1.00 | L3MBTL1 (0.67) | L3MBTL1KDRTEKCYP2D6CYP2C19 | |
| SCHEMBL21054693 | 0.87 | L3MBTL1 (0.69) | L3MBTL1KDRTEKCYP2D6CYP2C19 | |
| SCHEMBL30025561 | 0.87 | L3MBTL1 (0.69) | L3MBTL1KDRTEKCYP2D6CYP2C19 | |
| SCHEMBL511039 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP2D6CYP2C19ALDH1A1NPC1 | |
| SCHEMBL23462635 | 0.82 | L3MBTL1 (0.64) | L3MBTL1KDRTEKCYP2D6ALDH1A1 | |
| SCHEMBL21054717 | 0.79 | HSD17B10 (0.50) | L3MBTL1CYP2D6CYP2C19ALDH1A1NPC1 | |
| SCHEMBL30518368 | 0.79 | HSD17B10 (0.50) | L3MBTL1CYP2D6CYP2C19ALDH1A1NPC1 | |
| SCHEMBL27885869 | 0.77 | L3MBTL1 (0.76) | L3MBTL1KDRTEKALDH1A1EPHB4 | |
| SCHEMBL510536 | 0.77 | CREBBP (0.40) | L3MBTL1CYP2D6CYP2C19ALDH1A1NPC1 | |
| SCHEMBL26297955 | 0.77 | L3MBTL1 (0.40) | L3MBTL1CYP2D6CYP2C19ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2025-03-27 | — | — | US | disclosed |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2024-11-12 | — | — | US | disclosed |
| EP-3720438-B1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3720438-B1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-111698989-B | Heterocyclic substituted pyridine derivatives as antifungal agents | 安普利克斯制药公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-11512079-B2 | Heterocycle substituted pyridine derivative antifungal agents | AMPLYX PHARMACEUTICALS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2021-06-03 | — | — | US | disclosed |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2021-06-03 | — | — | US | disclosed |
| WO-2020247804-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247804-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3720438-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | Amplyx Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111698989-A | Heterocyclic substituted pyridine derivative antifungal agent | 安普利克斯制药公司 | 2020-09-22 | — | — | CN | disclosed |
| WO-2019113542-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113542-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | L3MBTL1 4543/4885KDR 3965/4885TEK 1741/4885 |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | L3MBTL1 4543/4885KDR 3965/4885TEK 1741/4885 |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | L3MBTL1 4543/4885KDR 3965/4885TEK 1741/4885 |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | ERG28, DPM1, CYP51A1 | L3MBTL1 4543/4885KDR 3965/4885TEK 1741/4885 |
| US-11512079-B2 | Heterocycle substituted pyridine derivative antifungal agents | ERG28, DPM1, CYP51A1 | L3MBTL1 4543/4885KDR 3965/4885TEK 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.